Immunosuppressants - GCC

In the GCC region, the revenue in the Immunosuppressants market is predicted to reach US$323.30m by 2024.
It is anticipated that there will be a steady annual growth rate (CAGR 2024-2029) of 15.30%, leading to a market volume of US$658.90m by 2029.
When compared globally, United States is expected to generate the highest revenue of US$35,470.00m in 2024.
The market for immunosuppressants in the GCC is experiencing a steady growth due to the increasing prevalence of autoimmune diseases in the region.

Key regions: Australia, Germany, United Kingdom, United States, France

Market

Region

Region comparison

Currency

Analyst Opinion

The demand for immunosuppressants in the Gulf Cooperation Council (GCC) region has been on the rise in recent years.

Customer preferences: The increase in demand for immunosuppressants in the GCC region can be attributed to the rising prevalence of autoimmune diseases and organ transplant surgeries. The region has a high prevalence of diseases such as rheumatoid arthritis, multiple sclerosis, and lupus, which require long-term treatment with immunosuppressants. In addition, the region has seen a rise in the number of organ transplant surgeries, which also require the use of immunosuppressants to prevent organ rejection.

Trends in the market: The immunosuppressants market in the GCC region is expected to continue to grow in the coming years. This growth can be attributed to several factors, including an increasing number of transplant surgeries, a growing elderly population, and rising prevalence of autoimmune diseases. The market is also expected to benefit from the introduction of new and innovative drugs.

Local special circumstances: One of the unique challenges facing the immunosuppressants market in the GCC region is the high prevalence of consanguineous marriages. This has led to a higher incidence of genetic diseases, which often require long-term treatment with immunosuppressants. In addition, the region has a high rate of obesity, which is a risk factor for several autoimmune diseases.

Underlying macroeconomic factors: The GCC region has a rapidly growing population, which is expected to drive demand for healthcare services, including immunosuppressants. The region is also investing heavily in healthcare infrastructure, which is expected to improve access to healthcare services for its citizens. In addition, the region has a high per capita income, which means that patients are able to afford expensive treatments such as immunosuppressants.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.